There is also considerable evidence that new state-of-the-art weight-loss drugs including GLP-1 agonists exert both weight-loss dependent and independent effects on liver metabolism to improve NASH in pre-clinical studies as reviewed [102]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.